Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Outcome Quality Standards in Pancreatic Oncologic Surgery in Spain
Journal Information
Vol. 96. Issue 6.
Pages 342-351 (June - July 2018)
Visits
749
Vol. 96. Issue 6.
Pages 342-351 (June - July 2018)
Original article
DOI: 10.1016/j.cireng.2018.03.003
Full text access
Outcome Quality Standards in Pancreatic Oncologic Surgery in Spain
Estándares de calidad en la cirugía oncológica pancreática en España
Visits
...
Luis Sabatera,b,
Corresponding author
luis.sabater@uv.es

Corresponding author.
, Isabel Moraa, Juan Manuel Gámez del Castilloa, Javier Escrig-Sosc, Elena Muñoz-Fornera, Marina Garcés-Albira, Dimitri Dorcarattoa, Joaquín Ortegaa,b
a Servicio de Cirugía General, Hospital Clínico Universitario de Valencia, Valencia, Spain
b Departamento de Cirugía, Universitat de València, Valencia, Spain
c Hospital General Universitario de Castellón, Castellón, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (2)
Table 1. Spanish Series of Pancreatic Cancer Surgery (2000–2016).
Table 2. Summarized Description of the Results of the Quality Indicators.
Show moreShow less
Abstract
Introduction

To establish quality standards in oncologic surgery is a complex but necessary challenge to improve surgical outcomes. Unlike other tumors, there are no well-defined quality standards in pancreatic cancer. The aim of this study is to identify quality indicators in pancreatic oncologic surgery in Spain as well as their acceptable limits of variability.

Methods

Quality indicators were selected based on clinical practice guidelines, consensus conferences, reviews and national publications on oncologic pancreatic surgery between the years 2000 and 2016. Variability margins for each indicator have been determined by statistical process control techniques and graphically represented with the 99.8 and 95% confidence intervals above and below the weighted average according to sample size.

Results

The following indicators have been determined with their weighted average and acceptable quality limits: resectability rate 71% (>58%), morbidity 58% (<73%), mortality 4% (<10%), biliary leak 6% (<14%), pancreatic fistula rate 18% (<29%), hemorrhage 11% (<21%), reoperation rate 11% (<20%) and mean hospital stay (<21 days).

Conclusions

To date, few related series have been published, and they present important methodological limitations. Among the selected indicators, the morbidity and mortality quality limits have come out higher than those obtained in international standards. It is necessary for Spanish pancreatic surgeons to adopt homogeneous criteria regarding indicators and their definitions to allow for the comparison of their results.

Keywords:
Quality standards
Pancreas
Oncologic resection
Pancreatic surgery
Resumen
Introducción

Identificar los estándares de calidad en la cirugía oncológica es un reto complejo necesario para poder mejorar los resultados quirúrgicos. A diferencia de lo que ocurre en otros tumores, no existen unos estándares de calidad bien definidos en el cáncer de páncreas. El objetivo es identificar los indicadores de calidad en la cirugía pancreática oncológica en España, así como sus límites de variabilidad.

Métodos

Los indicadores de calidad se han seleccionado a partir de las guías de práctica clínica, conferencias de consenso, revisiones y publicaciones de ámbito nacional sobre cirugía pancreática oncológica entre los años 2000–2016. Los márgenes de variabilidad para cada indicador se obtienen mediante estadística de control de procesos y gráficas de representación, teniendo en cuenta el tamaño de las series. Los límites de variabilidad se establecen a partir de la media y los intervalos de confianza al 95 y al 99,8%.

Resultados

Se han determinado los siguientes indicadores con sus medias y límites de calidad aceptables: tasa de resecabilidad 71% (> 58%), morbilidad 58% (< 73%), mortalidad 4% (< 10%), tasa de fístula biliar 6% (< 14%), tasa de fístula pancreática 18% (< 29%), hemorragia 11% (< 21%), tasa de reintervención 11% (< 20%) y estancia media (< 21 días).

Conclusiones

El número de series publicadas es muy escaso y presentan limitaciones metodológicas importantes. Entre los indicadores seleccionados, los límites de calidad de morbimortalidad han resultado más elevados que los obtenidos en los estándares internacionales. Es necesario que los cirujanos pancreáticos españoles adopten unos criterios homogéneos consensuados de los indicadores y su definición que permitan comparar sus resultados.

Palabras clave:
Estándares de calidad
Páncreas
Resección oncológica
Cirugía pancreática
Full Text
Introduction

Pancreatic cancer is the fourth cause of cancer death in Spain, and surgical resection is the only treatment that is able to increase survival.1,2 It is always a challenge for surgeons due to the technical difficulty of the procedure, and although mortality has been reduced in recent years, the rate of postoperative complications is still very high.3 Given the complexity of pancreatic surgery, it is necessary to establish standards that allow surgeons to assess the quality of the treatment provided and to consider what aspects should be improved, while comparing their results with those of other groups and specialized units. There is a great debate about which measurements should be used to determine surgical quality, as there are currently indicators for structure (case volume, availability of intensive care units or interventional radiology), procedure (perioperative antibiotic prophylaxis) and results (morbidity, mortality, pancreatic fistula rate).4

Standards would define the acceptable ranges of quality for a certain process and establish minimum permissible limits for specific indicators. This entails comparing the results from the management of a specific disease by means of measurable, valid and relevant indicators.5 Unlike what happens in other types of diseases where quality standards have been established (such as breast or colorectal cancer), in pancreatic cancer surgery there are no well-defined national standards, and only one study has published recommendations based on subjective criteria.6 Although approximations have been made based on objective international criteria,7 quality standards are influenced by multiple factors and those obtained in one country may not coincide with criteria established in another country or with those based on international reports. Therefore, it is necessary to define national quality standards and their variability ranges in order to establish what can be considered acceptable or unacceptable in the management of this disease.8 Consequently, the objective of our research has been to identify quality indicators for pancreatic cancer surgery in Spain, as well as its limits of variability according to a standardized methodology.

Material and MethodsResearch Strategy, Selection of Quality Indicators and Studies

The research process was carried out in 2 parts. First, it was necessary to identify which quality indicators have clinical relevance in pancreatic cancer surgery. To this end, a systematic search was conducted for clinical practice guidelines,9–15 consensus conferences16–19 and review studies about the quality of pancreatic cancer surgery and the development of indicators5,20–25 between 2000 and 2016 in MEDLINE/PubMed, Embase and Cochrane Library. Second, we proceeded with the systematic search of clinical research studies on oncological pancreatic surgery published in Spain between January 2000 and December 2016 that included a minimum of 20 surgical patients. To be selected, an indicator needed to have the following characteristics: be clinically relevant, so that it has an impact on prognosis or postoperative evolution; be clearly mentioned in the studies identified in the second part of the research, or values were able to be calculated easily from the data provided; and, appear with sufficient frequency to be able to be evaluated.

Statistical Analysis and Determining Standards

The standards for each quality indicator were determined by statistical techniques based on statistical process control.26–28 Control charts for the quantitative variables (X-charts) and control charts for attributes for the qualitative variables (P-charts) were made, representing the studies according to the number of cases included in each series from lowest to highest volume of patients. In the graphs, the main horizontal line corresponds with the average result of all the units compared, weighted mathematically by the volume of cases that each one contributes to the analysis; the limits of variability are represented by lines corresponding with the 99.8% confidence intervals (±3 standard errors) and 95% (±2 standard errors), respectively. Any result outside these limits deviates significantly from the weighted average (P<.002 and P<1.005, respectively) and is considered out of control according to the terminology of statistical process control. In our study, the acceptable quality limits for each indicator are defined within the 99.8% range. Therefore, if a result is within these limits, it is considered to be within quality standards. The 95 and 99.8% confidence intervals are limits that designate areas of alarm (99.8%) and precaution (95%); if a result is above or below them, it should be interpreted depending on the parameter we are measuring. Thus, for example, in the case of pancreatic fistula rate, if a result is below the limit of variability, it can be considered an excellent result; in contrast, in the case of the resectability rate, if the result is below the alarm zone, it is a negative result.

ResultsQuality Indicators and Selected Studies

The quality indicators selected for oncological pancreatic surgery were resectability rate, morbidity, mortality, pancreatic fistula rate, biliary fistula rate, hemorrhage, reoperation rate and mean hospital stay. A total of 20 series were identified,29–48 5 of which29,33,34 were excluded because they did not include a minimum of 20 patients. The results of the 15 selected series are shown in Table 1.

Table 1.

Spanish Series of Pancreatic Cancer Surgery (2000–2016).

References  Year  Patients, n  Resectability  Morbidity  Mortality  Bile duct fistula  Pancreatic fistula (definition)  Pancreatic fistula rate  Hemorrhage  Reoperation  Hospital stay 
García-Plata et al.32  2005  58    49.80  13.70  8.60  Amylase in discharge  22.40  5.17  20.60  – 
Balsells-Valls et al.35  2006  97  41.99  74.55  14.35  –  Not defined  22.50  26.70  6.40  26 
Jover et al.36  2006  80    46.70  6.60  6.60  Amylase×3  20.00  7.50  7.50  21 
Fernández-Cruz et al.37  2008  108    33.00  0.00  1.00  ISGPF  12.00  2.00  1.85  14 
Figueras et al.38  2008  56    72.00  5.40  4.50  ISGPF  12.50  7.00  27.50  22 
Sabater et al.39  2009  124  77.50  38.70  4.00  5.50  Amylase×3  6.25  6.45  3.80  17 
Montiel et al.40  2010  82    55.65  5.75  9.50  Amylase×3  11.40  8.40  10.45  10 
Busquets et al.41  2010  204    45.00  7.00  5.00  ISGPF  10.00  11.76  13.00  20 
Figueras et al.42  2013  123    64.20  5.00  6.00  ISGPF  24.50  16.00    14 
Dominguez-Comesaña et al.43  2013  117    48.71  5.13  7.89  Amylase×3  9.90  11.10  14.53  – 
Herrera-Cabezón et al.44  2015  480    58.05  1.05  –  ISGPF  22.50  –  10.15  17 
Rubio-Manzanares Dorado et al.45  2015  151  83.40  100.00  0.66  –  Not defined  –  –  10.50  18 
Landi et al.46  2015  78    58.97  5.00  10.25  ISGPF  11.50  12.82  8.97  19 
Sánchez Cabús et al.47  2015  129    77.50  4.70  7.80  ISGPF  34.80  14.70  12.40  24 
Morales Soriano et al.48  2015  85    42.30  2.40  3.50  ISGPF  16.45  –  11.50  16 

All the indicators present as percentages, except hospital stay, which is shown in days.

Resectability Rate

Only three series,35,39,45 with a total of 372 patients, reviewed the resectability rate. The weighted average was 71% and the acceptable quality limit was >58% (Fig. 1A).

Fig. 1.

Rate of resectability (A), morbidity (B) and mortality (C); each point represents a study included in Table 1.

Green: within standard limits with variability due to chance; yellow: warning zone but still within the 95% confidence interval; red: over the 99.8% limit and the results cannot be randomly attributed to the process analyzed.

(0.36MB).
Morbidity

Fifteen series,35–48 with a total of 1972 patients, included data on morbidity. The weighted average of this indicator was 58% and the acceptable quality limit was <73% (Fig. 1B).

Mortality

Mortality was evaluated in a total of 15 series,35–48 with a total of 1972 patients. In these series, the weighted average mortality was 4%, with an acceptable quality limit of <10% (Fig. 1C).

Pancreatic Fistula Rate

Pancreatic fistula rate was studied in 14 series32,35–44,46–48 for a total of 1821 patients. The weighted average was 18%, with an acceptable quality limit of <29%. It is important to note that there was great variability depending on the fistula definition used. Thus, the 14 studies that referred to pancreatic fistula rate presented several different definitions, with a variation among the rates reported between 6.25 and 34.8%.

The quality indicators selected for pancreatic cancer surgery were resectability rate, morbidity, mortality, pancreatic fistula rate, biliary fistula rate, hemorrhage, reoperation rate and mean stay. A total of 20 series were identified,29–48 5 of which29–31,33,34 were excluded because they did not include a minimum of 20 patients. The results of the 15 selected series are shown in Table 1.

When the pancreatic fistula rate was calculated in the series that followed the ISGPF criteria,37,38,41,42,44,46–48 the weighted average was 19%, while the acceptable quality limit was <31% (Fig. 2).

Fig. 2.

Rate of pancreatic fistula (A) and pancreatic fistula with ISGPF criteria (B); each point represents a study included in Table 1.

Green: within standard limits with variability due to chance; yellow: warning zone but still within the 95% confidence interval; red: over the 99.8% limit and the results cannot be randomly attributed to the process analyzed.

(0.26MB).
Biliary Fistula Rate

A total of 12 series32,36–43,46,48 including 1244 patients were evaluated to determine the rate of biliary fistula. The weighted average was 6%, with an acceptable quality limit of <14% (Fig. 3A).

Fig. 3.

Rate of biliary fistula (A) and hemorrhage (B); each point represents a study included in Table 1.

Green: within standard limits with variability due to chance; yellow: warning zone but still within the 95% confidence interval; red: over the 99.8% limit and the results cannot be randomly attributed to the process analyzed.

(0.23MB).
Hemorrhage

Hemorrhage of any origin (gastrointestinal, intra-abdominal) was evaluated from 12 series,32,35–43,46,47 totaling 1256 patients. The weighted average for hemorrhage was 11%, with an acceptable quality limit of <21% (Fig. 3B).

Reoperation Rate

The rate of reoperation was studied in 18 series,32,35–41,43–48 with a total of 1849 patients. The mean reoperation rate was 11%, with an acceptable quality limit of <20% (Fig. 4A).

Fig. 4.

Rate of reoperations (A) and average stay (B); each point represents a study included in Table 1.

Green: within standard limits with variability due to chance; yellow: warning zone but still within the 95% confidence interval; red: over the 99.8% limit and the results cannot be randomly attributed to the process analyzed.

(0.25MB).
Mean Hospital Stay

Mean hospital stay was calculated from 13 series35–42,44–48 with a total of 1797 patients. The mean stay was 18 days, with an acceptable quality limit of <21 days (Fig. 4B). The summarized description for each indicator with the weighted average and its limits of variability are shown in Table 2.

Table 2.

Summarized Description of the Results of the Quality Indicators.

  Weighted mean  99.8% CI  95% CI  Quality limit  Cases, n 
Rate of resectability  71  83–58  79–62  >58  372 
Morbidity  58  73–43  68–49  <73  1972 
Mortality  10–0  8–0  <10  1972 
Pancreatic fistula rate  18  29–7  25–10  <29  1821 
Bile duct fistula rate  14–0  11–1  <14  1244 
Hemorrhage  11  21–2  18–5  <21  1256 
Rate of reoperation  11  20–2  17–5  <20  1849 
Mean hospital stay  18  21–15  20–16  <21  1797 

All the indicators are presented as percentages, except mean hospital stay, which is shown in days.

Discussion

Pancreatic oncological resection is a technically complex procedure associated with a high incidence of postoperative complications. Therefore, the identification of quality standards is a very important element to reduce variability in surgical practice, improve results and optimize available resources.4,8 Research in quality standards is a difficult multidisciplinary challenge that includes not only structure and results indicators, but also process indicators.4,5 These indicators allow the surgeon to assess the results of the treatment performed, as well as to enable the comparison of these with other groups or specialized units.

Until now, the limited antecedents of proposed standards in hepatobiliary surgery in our healthcare system focused on perioperative morbidity and mortality and case volume. This is similar to the study published by Figueras et al.6 in 2002, which established standards for mortality and morbidity (<10 and <50%, respectively) for periampullary tumors, below which they do not recommend performing these procedures, as well as a minimum number of annual procedures that should be performed at the hospital (24 annual pancreaticoduodenectomies). Recently, Herrera-Cabezón et al.44 have reviewed a series of 480 pancreatic resections in comparison with international standards,7 with excellent results in terms of compliance with quality criteria. In the present study, we have tried to identify the quality standards and their limits of acceptable variability in pancreatic cancer surgery in Spain, based on publications in our country. Compared with data from the international literature,7 we found a similar resectability rate, but the acceptable quality limits for morbidity and mortality indicators are higher in the Spanish series: <73 vs <55% and <10 vs <5%, respectively.

The most important problem that arises when carrying out a study with this methodology is that it depends on the information that the different researchers have considered relevant to publish and is available in the series. Thus, there is information that is considered very important from the point of view of quality, such as the annual volume of cases, the R0 resection rate, overall survival or disease-free survival which, since it is not available in a minimum number of articles, cannot be analyzed. In this sense, this present study contrasts with the international standard study, where such information was available.7 Another difficulty that must be highlighted is the lack of definitions that different authors consider to assess and present their results. Although there is already consensus about the definitions of the majority of complications,49–51 these have not been used in the published Spanish series, except for pancreatic fistula rate, which considered the ISGPF criteria in 8 of the 15 series. This implies that the incidence of complications shows great disparity, depending on the definition applied in each study. Despite these limitations, this study represents an initial attempt at obtaining indicators and their acceptable variability in oncological pancreatic surgery in our setting.

Furthermore, an additional element that our research highlights is the limited number of pancreatic surgery series published in Spain during the last 16 years, many of which with a small number of patients: Only since 2008 have series been published with more than 100 patients. In conclusion, we have defined a series of indicators in pancreatic cancer surgery in Spain, as well as their quality limits, according to a standardized methodology. Our research shows the limited number of series published, which present important methodological limitations, highlighting the heterogeneity and the lack of definition of the parameters used. It is necessary for researchers to adopt homogeneous criteria for the definition of relevant indicators, which would allow for comparison of results and an assessment of which aspects should be improved for the benefit of patients treated with pancreatic cancer resection. Despite such limitations, this study offers currently available information, providing a reference with which to compare different national groups.

Authorship

All the authors have participated in the research study and in the review of the manuscript: LS and JES designed the study; LS, IM and JMGC identified the articles for inclusion and the selected indicators; LS, IM and JES conducted the statistical analyses; LS, IM and JMGC composed the first version of the manuscript; and EMF, MGA, DD and JO gave their critical review and final approval of the manuscript.

Conflict of Interests

The authors have no conflict of interests to declare.

References
[1]
A.P. Stark, G.D. Sacks, M.M. Rochefort, T.R. Donahue, H.A. Reber, J.S. Tomlinson, et al.
Long-term survival in patients with pancreatic ductal adenocarcinoma.
Surgery, 159 (2016), pp. 1520-1527
[2]
A. Paniccia, P. Hosokawa, W. Henderson, R.D. Schulick, B.H. Edil, M.D. McCarter, et al.
Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma.
JAMA Surg, 150 (2015), pp. 701-710
[3]
L. Fernández-Cruz, L. Sabater, J. Fabregat, U. Boggi.
Complicaciones después de una pancreaticoduodenostomía.
[4]
J.D. Birkmeyer, J.B. Dimick, N.J. Birkmeyer.
Measuring the quality of surgical care: structure, process, or outcomes?.
J Am Coll Surg, 198 (2004), pp. 626-632
[5]
B.T. Kalish, C.M. Vollmer, T.S. Kent, W.H. Nealon, J.F. Tseng, M.P. Callery.
Quality assessment in pancreatic surgery: what might tomorrow require?.
J Gastrointest Surg, 17 (2013), pp. 86-93
[6]
J. Figueras, C. Valls, J. Fabregat, T. Serrano, E. Jaurrieta.
Equipamiento, experiencia mínima y estándares en la cirugía hepatobiliopancreática (HBP).
Cir Esp, 71 (2002), pp. 201-206
[7]
L. Sabater, A. García-Granero, J. Escrig-Sos, M.C. Gómez-Mateo, J. Sastre, A. Ferrández, et al.
Outcome quality standards in pancreatic oncologic surgery.
Ann Surg Oncol, 21 (2014), pp. 1138-1146
[8]
M. Pera.
Variabilidad en la práctica quirúrgica. Un problema por resolver.
[9]
D.B. Evans, J.M. Jessup, T. Colacchio.
Pancreatic cancer surgical practice guidelines. Pancreatic Cancer Practice Guideline Committee.
Oncology, 11 (1997), pp. 1074-1079
[10]
M.A. Tempero, S. Behrman, E. Ben-Josef, A.B. Benson 3rd, J.L. Cameron, E.S. Casper, et al.
Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw, 3 (2005), pp. 598-626
[11]
M.A. Tempero, M.P. Malafa, S.W. Behrman, A.B. Benson 3rd, E.S. Casper, E.G. Chiorean, et al.
Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.
J Natl Compr Canc Netw, 12 (2014), pp. 1083-1093
[12]
S. Cascinu, M. Falconi, V. Valentini, S. Jelic, ESMO Guidelines Working Group.
Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol, 21 (2010), pp. v55-v58
[13]
K. Yamaguchi, M. Tanaka, Committee for Revision of Clinical Guidelines for Pancreatic Cancer of Japan Pancreas Society.
EBM-based Clinical Guidelines for Pancreatic Cancer 2009 from the Japan Pancreas Society: a synopsis.
Jpn J Clin Oncol, 41 (2011), pp. 836-840
[14]
M.B. Ujiki, M.S. Talamonti.
Guidelines for the surgical management of pancreatic adenocarcinoma.
Semin Oncol, 34 (2007), pp. 311-320
[15]
Pancreatic Section, British Society of Gastroenterology; Pancreatic Society of Great Britain and Ireland; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland; Royal College of Pathologists; Special Interest Group for Gastro-Intestinal Radiology.
Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.
[16]
K. Takaori, C. Bassi, A. Biankin, T.B. Brunner, I. Cataldo, F. Campbell, et al.
International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer.
Pancreatology, 16 (2016), pp. 14-27
[17]
J.L. Van Laethem, C. Verslype, J.L. Iovanna, P. Michl, T. Conroy, C. Louvet, et al.
New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.
Ann Oncol, 23 (2012), pp. 570-576
[18]
M. Martin-Richard, A. Ginès, J.R. Ayuso, L. Sabater, J. Fabregat, R. Mendez, et al.
Recomendaciones para el diagnóstico, la estadificación y el tratamiento de las lesiones premalignas y el adenocarcinoma de páncreas.
Med Clin (Barc), 147 (2016), pp. 465.e1-465.e8
[19]
S. Navarro, E. Vaquero, J. Maurel, J.A. Bombí, C. de Juan, J. Feliu, et al.
Recomendaciones para el diagnóstico, estadificación y tratamiento del cáncer de páncreas (parte ii).
Med Clin (Barc), 134 (2010), pp. 692-702
[20]
K.Y. Bilimoria, D.J. Bentrem, K.D. Lillemoe, M.S. Talamonti, C.Y. Ko.
Assessment of pancreatic cancer care in the United States based on formally developed quality indicators.
J Natl Cancer Inst, 101 (2009), pp. 848-859
[21]
T.S. Riall, W.H. Nealon, J.S. Goodwin, C.M. Townsend, J.L. Freeman.
Outcomes following pancreatic resection: variability among high-volume providers.
[22]
J.B. Dimick, H.G. Welch, J.D. Birkmeyer.
Surgical mortality as an indicator of hospital quality. The problem with small sample size.
JAMA, 292 (2004), pp. 847-851
[23]
M.A. Tempero, J. Berlin, M. Ducreux, D. Haller, P. Harper, D. Khayat, et al.
Pancreatic cancer treatment and research: an international expert panel discussion.
Ann Oncol, 22 (2011), pp. 1500-1506
[24]
M.L. McGory, P.G. Shekelle, L.Z. Rubenstein, A. Fink, C.Y. Ko.
Developing quality indicators for elderly patients undergoing abdominal operations.
J Am Coll Surg, 201 (2005), pp. 870-883
[25]
C.M. Vollmer Jr., W. Pratt, T. Vanounou, S.K. Maithel, M.P. Callery.
Quality assessment in high-acuity surgery: volume and mortality are not enough.
Arch Surg, 142 (2007), pp. 371-380
[26]
D.J. Spiegelhalter.
Funnel plots for institutional comparison.
Qual Saf Health Care, 11 (2002), pp. 390-391
[27]
D.J. Spiegelhalter.
Funnel plots for comparing institutional performance.
Statist Med, 24 (2005), pp. 1185-1192
[28]
J. Escrig-Sos.
Métodos actuales para la monitorización y control de calidad de los procesos clínicos.
Rev Senol Patol Mamar, 27 (2014), pp. 94-98
[29]
J. Boadas, J. Balart, G. Capellà, F. Lluis, A. Farré.
Survival of cancer of the pancreas. Bases for new strategies in diagnosis and therapy.
Rev Esp Enferm Dig, 92 (2000), pp. 316-325
[30]
B. Pérez-Cabrera, B. Sánchez, F. Luque, E. Gómez, F. Bravo, F. Pérez.
Tratamiento quirúrgico de los adenocarcinomas de la ampolla de Vater.
Cir Esp, 67 (2000), pp. 21-24
[31]
V. Pla, A. Pallas, M.D. Ruiz, C. Fernández, C. Flors, J.V. Roig.
La pancreatogastrostomía en la reconstrucción tras duodenopancreatectomía cefálica por patología maligna de la región periampular.
Cir Esp, 72 (2002), pp. 14-17
[32]
E. García-Plata, J.L. Seco, M. Plaza, O. Vidal, M.A. Álvarez, I.L. Botín, et al.
Influencia del drenaje biliar prequirúrgico en el postoperatorio de la duodenopancreatectomía cefálica.
Cir Esp, 77 (2005), pp. 203-207
[33]
J.A. Fraguela-Mariña, L. Taboada-Filgueira, C. Fernández-Blanco, C. Gómez.
Pancreatoyeyunostomía en «doble corona» tras duodenopancreatectomía cefálica.
Cir Esp, 75 (2004), pp. 207-209
[34]
J.M. Ramia, K. Muffak, A. Palomeque, A. Mansilla, J. Villar, D. Garrote, et al.
Pancreatectomíacorporocaudal: una misma técnica con variadas indicaciones.
Cir Esp, 77 (2005), pp. 22-26
[35]
J. Balsells-Valls, J.J. Olsina-Kissler, I. Bilbao-Aguirre, A. Solans-Doménech, C. Margarit-Creixell, M. Armengol-Carrasco.
Tratamiento quirúrgico de la neoplasia de páncreas y región periampular en una unidad especializada: una década después.
Gastroenterol Hepatol, 29 (2006), pp. 66-70
[36]
J.M. Jover, A. Carabias, S. Fuerte, R. Ríos, I. Ortega, M. Limones.
Resultados de la derivación con 2 asas tras duodenopancreatectomía cefálica.
Cir Esp, 80 (2006), pp. 373-377
[37]
L. Fernández-Cruz, R. Cosa, L. Blanco, M.A. López-Boado, E. Astudillo.
Pancreatogastrostomy with gastric partition after pylorus-preserving pancreatoduodenectomy versus conventional pancreatojejunostomy. A prospective randomized study.
Ann Surg, 248 (2008), pp. 930-938
[38]
J. Figueras, A. Codina-Barreras, S. López-Ben, A. Maroto, S. Torres-Bahí, H. Daniel Gonzalez, et al.
Duodenopancretectomía cefálica en tumores periampulares. Disección de la arteria mesentérica superior como abordaje inicial. Descripción de la técnica y evaluación de nuestra experiencia inicial.
Cir Esp, 83 (2008), pp. 186-193
[39]
L. Sabater, J. Calvete, L. Aparisi, R. Cánovas, E. Muñoz, R. Añón, et al.
Neoplasias de páncreas y periampulares: morbimortalidad, resultados funcionales y supervivencia a largo plazo.
[40]
M.C. Montiel Casado, F. Pardo Sánchez, F. Rotellar Sastre, P. Martí Cruchaga, F.J. Álvarez Cienfuegos.
Experiencia de un programa de fast-track en la duodenopancreatectomía cefálica.
[41]
J. Busquets, J. Fabregat, R. Jorba, N. Peláez, F. García-Borobia, C. Masuet, et al.
Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (Parte 1). Complicaciones postoperatorias en 204 casos en un centro de referencia.
[42]
J. Figueras, L. Sabater, P. Planellas, E. Muñoz-Forner, S. Lopez-Ben, L. Falgueras, et al.
Randomized clinical trial of pancreaticogastrostomy versus pancreaticojejunostomy on the rate and severity of pancreatic fistula after pancreaticoduodenectomy.
Br J Surg, 100 (2013), pp. 1597-1605
[43]
E. Dominguez-Comesaña, F.J. Gonzalez-Rodriguez, J.L. Ulla-Rocha, A. Lede-Fernandez, J.L. Portela-Serra, M.A. Piñon-Cimadevila.
Morbimortalidad de la resección pancreática.
Cir Esp, 91 (2013), pp. 551-558
[44]
F.J. Herrera-Cabezón, P. Sánchez-Acedo, C. Zazpe-Ripa, A. Tarifa-Castilla, J.M. Lera-Tricas.
Estándares de calidad en 480 resecciones pancreáticas: estudio prospectivo observacional.
Rev Esp Enferm Dig, 107 (2015), pp. 152-161
[45]
M. Rubio-Manzanares Dorado, L.M. Marín Gómez, D. Aparicio Sánchez, G. Suárez Artacho, C. Bellido, J.M. Álamo, et al.
Implicaciones de las variantes arteriales hepáticas durante la duodenopancreatectomía cefálica oncológica.
Rev Esp Enferm Dig, 107 (2015), pp. 417-422
[46]
F. Landi, C. Dopazo, G. Sapisochin, M. Beisani, L. Blanco, M. Caralt, et al.
Duodenopancreatectomía cefálica con resección de la vena mesentérica superior y vena porta por adenocarcinoma de la cabeza de páncreas: experiencia y resultados a largo plazo de Hospital Universitario Vall d’Hebron.
[47]
S. Sánchez Cabús, D. Saavedra, J. Sampson, M. Cubel, M.A. López-Boado, J. Ferrer, et al.
Resultados de la pancreatogastroanastomosis con bipartición gástrica después de duodenopancreatectomía con preservación pilórica.
[48]
R. Morales Soriano, N. Esteve Pérez, S. Tejada Gavela, A. Cuadrado García, J.C. Rodríguez Pino, J.M. Morón Canis, et al.
Resultados de la rehabilitación multimodal en la duodenopancreatectomía cefálica.
[49]
C. Bassi, C. Dervenis, G. Butturini.
Postoperative pancreatic fistula: an international study group (ISGPF) definition.
[50]
D. Dindo, N. Demartines, P.A. Clavien.
Classification of surgical complications. A new proposal with evaluation in a cohort of 6336 patients and results of a survey.
Ann Surg, 240 (2004), pp. 205-213
[51]
M.N. Wente, J.A. Veit, C. Bassi, C. Dervenis, A. Fingerhut, D.J. Gouma, Postpancreatectomy hemorrhage (PPH): An International Study Group of Pancreatic Surgery (ISGPS) definition, et al.
Surgery, 142 (2007), pp. 20-25

Please cite this article as: Sabater L, Mora I, Gámez del Castillo JM, Escrig-Sos J, Muñoz-Forner E, Garcés-Albir M, et al. Estándares de calidad en la cirugía oncológica pancreática en España. Cir Esp. 2018;96:342–351.

The information contained in this manuscript was presented as an oral communication at the 31st National Surgery Congress of the AEC in November, 2016 in Madrid.

Copyright © 2018. AEC
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.